These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33103220)

  • 1. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.
    Deganutti G; Prischi F; Reynolds CA
    J Comput Aided Mol Des; 2021 Feb; 35(2):195-207. PubMed ID: 33103220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
    Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
    Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
    Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
    Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Potential Allosteric Site in the SARS-CoV-2 Spike Protein and Targeting Allosteric Inhibitor to Stabilize the RBD Down State using a Computational Approach.
    Li T; Yan Z; Zhou W; Liu Q; Liu J; Hua H
    Curr Comput Aided Drug Des; 2024; 20(6):784-797. PubMed ID: 37493168
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Tiwari V
    Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
    Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor.
    Müller WEG; Neufurth M; Schepler H; Wang S; Tolba E; Schröder HC; Wang X
    Biomater Sci; 2020 Dec; 8(23):6603-6610. PubMed ID: 33231598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
    Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
    Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
    Rui L; Haonan L; Wanyi C
    Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
    Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
    Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based Virtual Screening from Natural Products as Inhibitors of SARS-CoV-2 Spike Protein and ACE2 Receptor Binding and their Biological Evaluation
    Delgado-Maldonado T; Gonzalez-Morales LD; Juarez-Saldivar A; Lara-Ramírez EE; Rojas-Verde G; Moreno-Rodriguez A; Bandyopadhyay D; Rivera G
    Med Chem; 2024; 20(5):546-553. PubMed ID: 38204279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
    Egieyeh S; Egieyeh E; Malan S; Christofells A; Fielding B
    PLoS One; 2021; 16(1):e0245258. PubMed ID: 33417604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
    Mehdipour AR; Hummer G
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.